ExpertiseUpdated on 18 May 2026
Expertise Offer
EU Technology & Funds Manager at TİGA
Ankara, Türkiye
About
TIGA Information Technologies Inc was established in 2007 to drive healthcare forward with its proven technology. From the first day, we started to serve, we focused on innovation, cutting-edge technology, and quality by putting patient safety at the center. Our main goal is to create a comprehensive digital health ecosystem so that everyone can access healthcare services more efficiently and benefit equally. To make this vision real, TIGA has been developing products and solutions in the health IT sector, especially in the fields of drug traceability, healthcare interoperability, patient engagement, pharma management, population health management, and personalized healthcare. TIGA has a wide range of product scales for ensuring patient safety, empowering healthcare authorities, and providing healthcare interoperability. Almost all of these products have been used in various national and international scale projects such as the Turkish National Healthcare System, the Qatar Health Information Exchange Hub, the Central E-Prescription System of Turkey, the Central E-Prescription System of Qatar, Turkish Pharmaceutical Track & Trace System, Saudi Drug Track and Trace System, Qatar Pharmaceutical Track &Trace System, and many more.
Similar opportunities
Project cooperation
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Elifnaz Unay Kılıç
EU Technology & Funds Manager at TİGA
Ankara, Türkiye
Project cooperation
- Planning
- Consortium looking for partners
Miadreza Shafiekhah
Head of Research and Innovation at Nowocert
Dublin, Ireland
Expertise
Montse Cruz Gatell
EITs Master contact at University of Barcelona
Barcelona, Spain